NovaBridge Biosciences
NASDAQ:NBPBiotechnology
-$0.07 today
- Market cap
- $104.10M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.90M
NBP Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
NovaBridge BiosciencesNASDAQ: NBP
Net Debt · Q4 FY2025 · quarter ended Dec 2025
Net debt remains negative
Q4 FY2025 net debt was -$29.67M, compared with -$469.9M a year earlier.
Context
- Net debt amounted to 79.7% of total assets at the end of Q4 FY2025, up 49.4 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +93.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
Mixed currencies · from the balance sheet
- Latest · FY2025
- (29.67M) USD
- Year-over-year change
- —
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.67M) | — |
| FY2024 | 2024-12-31 | (469.9M) | -63.4% |
| FY2023 | 2023-12-31 | (287.62M) | +90.9% |
| FY2022 | 2022-12-31 | (3.18B) | -493.4% |
| FY2021 | 2021-12-31 | (535.16M) | — |
Net Debt vs competitors
How NBP compares with its peers on the latest reported figures
- NBP's Dec 2025 net debt of -$29.67M is the 7th highest of the 11 companies compared; the peer median is -$23.21M.
- Its year-over-year change of +93.7% is the highest of 11, against a peer median of -24.4%.
- Net debt amounts to 79.7% of total assets for NBP, versus a peer median of 13.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $121.61M | +20.9% | +76.0% | 771.7% | |
| Mar 2026 | $5.9M | -18.9% | — | 5.4% | |
| Mar 2026 | -$4.66M | -104.8% | — | 8.8% | |
| Mar 2026 | -$10.04M | +12.9% | — | 4.4% | |
ENGNenGene Holdings Inc. | Apr 2026 | -$21.58M | +33.0% | — | 7.0% |
| Mar 2026 | -$24.85M | -1.6% | — | 8.7% | |
NBPNovaBridge Biosciences | Dec 2025 | -$29.67M | +93.7% | — | 79.7% |
| Mar 2026 | -$61.75M | -30.0% | — | 18.4% | |
| Mar 2026 | -$67.8M | -242.7% | — | 49.2% | |
| Mar 2026 | -$149.77M | -117.7% | — | 57.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | -$317.21M | -2931.4% | — | 80.6% |
| Peer median (excluding NBP) | -$23.21M | -24.4% | +76.0% | 13.6% | |
Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · CNY | FY2022 Dec 2022 · CNY | FY2023 Dec 2023 · CNY | FY2024 Dec 2024 · CNY | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 552.8M | 3.21B | 291.51M | 498.24M | 30.11M |
| Short-term Investments | 118.16M | 235.43M | 20.22M | 767.36M | 30.02K |
| Net Receivables | 60.95M | 4.81M | 1.83M | 8.55M | 256.33K |
| Inventory | 4.27M | (80.28M) | 0 | 0 | 0 |
| Other Current Assets | 0 | 242.96M | 15.68M | 1 | 0 |
| Total Current Assets | 750.18M | 3.63B | 329.91M | 1.29B | 31.1M |
| Property, Plant & Equipment (Net) | 24.87M | 123.97M | 5.55M | 27.72M | 421.59K |
| Goodwill | 25.51M | 162.57M | 0 | 0 | 0 |
| Intangible Assets | 18.77M | 118.89M | 0 | 0 | 0 |
| Long-term Investments | 55.24M | 30.85M | 0 | 224.98M | 5.32M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.18M | 10.91M | 33.46M | 9.96M | 402K |
| Total Non-current Assets | 128.56M | 447.19M | 39.01M | 262.66M | 6.15M |
| Total Assets | 878.74M | 4.07B | 368.92M | 1.55B | 37.24M |
| Account Payables | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | 2.75M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 371.66K | 2.19M | 0 | 773.67K | 0 |
| Other Current Liabilities | 0 | 549.85M | 49.67M | 5.01M | 1.31M |
| Total Current Liabilities | 97.9M | 659.74M | 58.14M | 61.7M | 3.84M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 37.49M | 0 | 106K | 0 | 0 |
| Other Non-current Liabilities | 15.2M | 373.53M | 64.83M | 3.8K | 73.05K |
| Total Non-current Liabilities | 65.52M | 405.6M | 68.19M | 22.38M | 384.13K |
| Total Liabilities | 163.42M | 1.07B | 126.34M | 84.08M | 4.23M |
| Common Stock | 19.77K | 132K | 19K | 138.68K | 3.86K |
| Retained Earnings | (683.21M) | (6.77B) | (1.26B) | (9.39B) | (190.47M) |
| Accumulated OCI | (29.26M) | 216.72M | 39.77M | 243.66M | 5.94M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 715.33M | 3.01B | 242.58M | 1.47B | 33.02M |
| Total Debt | 17.64M | 38.29M | 3.89M | 28.33M | 438.46K |
| Net Debt | (535.16M) | (3.18B) | (287.62M) | (469.9M) | (29.67M) |
NovaBridge Biosciences
NASDAQ:NBP
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.